RxDoctor Payments Data

David Gaskin, MD

Internal Medicine · Savannah, GANPI 1952340291

Payments from drug & device makers

$44,905in general payments, 2019–2025

Across 893 payments — averaging $50.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$31K
  • AbbVie$2K
  • Novo Nordisk$1K
  • Amgen$934
  • Pfizer$806
  • Johnson & Johnson$731
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$13,83099%
  • Education$1611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer23$31,089
AbbVie(2 entities)143$1,909
Novo Nordisk116$1,408
Amgen(2 entities)47$934
Pfizer57$806
Johnson & Johnson(2 entities)52$731
Novartis53$730
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC36$608
GSK28$567
Astellas Pharma US Inc27$515
Lilly USA, LLC29$428
AstraZeneca(2 entities)23$391
Boehringer Ingelheim21$381
Otsuka America Pharmaceutical, Inc.17$369
Esperion Therapeutics, Inc.19$277
Amarin Pharma, Inc.13$238
Dexcom, Inc.10$216
Merck13$193
Sunovion Pharmaceuticals Inc.13$190
Idorsia Pharmaceuticals US Inc8$172
Lucid Diagnostics Inc.2$163
Ironwood Pharmaceuticals, Inc8$158
Radius Health, Inc.6$137
Biohaven Pharmaceuticals, Inc.7$126
Currax Pharmaceuticals LLC9$125
Exact Sciences8$122
Pacira Therapeutics, Inc.1$106
Sumitomo Pharma America, Inc.6$97
Biohaven Pharmaceutical Holding Company Ltd.4$97
Eisai Inc.5$91
E.r. Squibb & Sons, L.L.C.6$89
Lundbeck LLC4$86
Sanofi-aventis U.S. LLC5$81
Kowa Pharmaceuticals America, Inc.5$71
Mylan Specialty L.p.3$70
Axsome Therapeutics, Inc.3$62
Teva Pharmaceuticals USA, Inc.4$57
Sanofi Pasteur Inc.3$47
Phathom Pharmaceuticals, Inc.4$45
Pulmonx Corporation1$45
Xeris Pharmaceuticals, Inc.2$45
Genentech USA, Inc.3$44
Biogen3$41
Jazz Pharmaceuticals Inc.2$40
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$37
Shield Therapeutics Inc2$36
Boston Scientific2$36
Medtronic2$36
Madrigal Pharmaceuticals2$34
Endo Pharmaceuticals Inc.2$33
Hikma Pharmaceuticals USA2$32
Abiomed1$32
Arbor Pharmaceuticals, Inc.2$31
Insulet Corporation2$31
Clarus Therapeutics Inc.2$29
Redhill Biopharma Inc.1$25
VBI Vaccine (delaware) Inc.1$22
Cvrx, Inc.1$22
Vapotherm Inc1$21
Kyowa Kirin, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,905 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$230,759
Medicare patients
455
Services billed
4,658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide183$281,309
FarxigaDapagliflozin Propanediol200$209,232
TrulicityDulaglutide159$203,836
MounjaroTirzepatide125$130,596
EliquisApixaban102$121,906
Trelegy ElliptaFluticasone/Umeclidin/Vilanter96$110,502
JardianceEmpagliflozin90$101,887
JanuviaSitagliptin Phosphate36$53,334
XareltoRivaroxaban35$49,235
GemtesaVibegron34$37,491
LinzessLinaclotide29$36,762
Tresiba Flextouch U-100Insulin Degludec28$23,539
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$23,344
Repatha SureclickEvolocumab15$22,136
KerendiaFinerenone16$14,141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$428$334,432284 claims
Novo NordiskOzempic$1,408$281,309183 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$391$246,589258 claims
PfizerEliquis$806$121,906102 claims
GSKTrelegy Ellipta, Shingrix$567$115,971121 claims
Boehringer IngelheimJardiance$381$101,88790 claims
MerckJanuvia$193$53,33436 claims
Johnson & JohnsonXarelto$731$49,23535 claims
Sumitomo Pharma America, Inc.Gemtesa$97$37,49134 claims
AbbVieLinzess$1,909$36,76229 claims
BayerKerendia$31,089$14,14116 claims
Esperion Therapeutics, Inc.Nexlizet$277$8,87317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →